Clinical and Bacteriological Evaluation of Netilmicin in Gram-Negative Infections | Zendy

Jean Klášterský | Zendy; F. Meunier–Carpentier | Zendy; L. Coppens-Kahan | Zendy; D. Daneau | Zendy; JeanMarie Prevost | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical and Bacteriological Evaluation of Netilmicin in Gram-Negative Infections

Author(s) -

Jean Klášterský,

F. Meunier–Carpentier,

L. Coppens-Kahan,

D. Daneau,

JeanMarie Prevost

Publication year - 1977

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.12.4.503

Subject(s) - netilmicin , gentamicin , aminoglycoside , antibiotics , medicine , pseudomonas aeruginosa , microbiology and biotechnology , creatinine , biology , tobramycin , bacteria , genetics

A preliminary study was conducted with netilmicin, a new aminoglycoside antibiotic. Its effectiveness was evaluated in vitro against 546 strains of Enterobacteriaceae and Pseudomonas aeruginosa isolated from clinical material. Its effectiveness against gentamicin-susceptible strains was roughly similar to that of gentamicin and other newer aminoglycoside antibiotics. Cross-resistance to netilmicin was found in 9 of 44 gentamicin-resistant strains. A favorable clinical response was observed in 70% of the patients treated with a dose of netilmicin ranging from 4.5 to 7.5 mg/kg. However, the appearance of granular casts was seen in 7 of 10 patients receiving the higher dosage of netilmicin (7.5 mg/kg) and a rise in blood urea nitrogen or serum creatinine levels was observed in 5 of these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research